A British investor has injected another $40 million into Northwest Biotherapeutics, fueling the Maryland company’s increasingly promising pursuit of new vaccine therapies targeting both operable and inoperable cancers.
Neil Woodford, through his investment venture Woodford Equity Income Fund, will purchase roughly 5 million shares of Northwest Bio’s stock at $7.40 per share, totaling $40 million, the company announced this week. This latest infusion follows a $25 million stake Woodford took in the Bethesda-based company in September and, through a series of smaller stock purchases over the past year, brings his investment firm’s total stake in Northwest Bio near $100 million.
Woodford’s portfolio includes large stakes in some of the world’s biggest pharmaceutical companies, such as AstraZeneca and GlaxoSmithKline.
“This gives us the resources we need to ramp up our programs, and it will help us advance both of our two major product lines,” Linda Powers, chief executive at Northwest Bio, said in an interview.
Often, potential successes like this in the biotech sector capture the attention of the industry’s largest players, making Northwest Bio a possible acquisition target. However, Powers says being bought out isn’t the ideal plan.
“That’s always a possible road forward,” she said when asked about the likelihood of an acquisition. “But when there’s a whole new category of medical technology that didn’t exist before, which is what we believe we have with these immune therapies, there’s an opportunity to build the dominant player in that new category.”
She added: “Our preference — and we think we are positioned to have a real shot at this — would be to become that new dominant player.”
Those two product lines consist of cell-based vaccines that the company, which was founded in 1996, has developed to harness the body’s immune system to attack solid cancer tumors. One of those treatments is intended to fight cancers — particularly brain cancer — that can be surgically removed. That product is currently in late-stage trials, and the tests are scheduled to conclude next year.
Meanwhile, Northwest Bio is in the earlier stages of testing vaccines to treat inoperable cancers — ones surgeons cannot go in and extract.
This latest financing round comes less than a week after the company presented data in Munich, Germany showing that a recent trial featuring 51 brain cancer patients showed significantly longer-than-expected survival for those receiving the former treatment (for operable cancers). The treatment showed success even with some of the most aggressive types of cancers.
“That’s obviously very exciting, both for us and for patients,” Powers said. “It has been a long road, but we’re nearing the finish line.”
We all know there are huge volumes of April $7 strike call options traded and huge July $6 strike put option traded so far. Although there are numerous possibilities in terms of what really its implications. But it seems the most likely possibility in general is that Sir Woodford had initiated both these two large pools of option trading:
He bought those calls funded by his selling of those puts since he believes the good data are coming and his financial strength behind his commitment or conviction of going long NWBO on the context of knowing that he would had a major financing deal with the company , i.e., the recently announced $40 million deals with the company.
On the other hand, the shorts thought that the company was in desperation of needing funding to fund its existing L trials, the future D trials, etc., and did not believe the company could get any favorable deal with anybody. They initiated those call selling (to Woodford, etc. unfortunately for the shorts) hoping to pocket the premiums while driving the price down further. Again the shorts thought the price would further decline by July after the ASCO hype withered, so they took the bite of those July put selling (from Woodford, etc.) and ended up of bought those puts.
Now, we have known Sir Woodford has been winning the battle as the share price steadily and continually appreciated: he has been either exercising his deep in money call options or simply closing those profitable call operation as the shorts have to deliver those shares to him via either buying in the open market at increasingly higher price as each day passes by.
The irony of the situation is that the currently share price appreciation may be actually in part (or a major part) is fueled by the shorts. LOL!
Of course, because of the dynamics shift in favor longing the stock, more and more retail investors have firmed in the support of the long institutions represented by Sir Woodford.
Yes, the idiot in IHub has made the number of pseudo progression patients at 24 as if it is a fact. Now we know only one patient is confirmed to be pseudo pression. Yes, as you said for most conservative point of view (impossible) by assuming all those 25 indeterminate patients are pseudo, the results are sill unbelievable positive and unheard of.
Pyrr, aka, steve is no longer the Pyrr or steve you know. His soul is now bought by (?) no different than anyone else who sell his soul.
You came out with a conclusion based on only one side of him (his recent commentaries) but you need to make your conclusion based on all his commentaries/history. He is no more than a bipolar if you combine all his commentaries with correlation with his sell and buy 'recommendation" history. That's it, a bipolar!
It's nothing wrong to have his view changed or not, changed how often or changed for his own personal purpose, but it is wrong to pretend he is no so, evidenced by you one of his victim, if you have heeded his call and buy some put!
As far as the stock price is concerned, you and he are now just spreading FUDs, nothing more or less!
JFYI: nobody, even cramer would have had any impact on stock prices, particularly those of small caps, if he has not been willing to serve as "unofficial representative" or "front" for some funds, long or shorts behind the scene each time and every time the stock price is manipulated. [Pyrr may have to work hard for next 100 years before he has any chance to be one Cramer or even AF]
Pyrr is nobody, me nobody either. You know that and we all know that and he knows that even more so, although he may think otherwise after a few drinks. Anyone can write SA articles. The movement of the underlying share price is not impacted by how many SA articles and/or the qualities of the articles one may write, but related to whether there are any funds behind it. [Only Pyrr knows does he get money from any fund?]
Now please leave him in his IHUB village, never ever bring him to this board. Of course, you have the right of freedom of speech.
Our yahooers' price target is $30 before either of L and D results are known; $60 ~ $100 for the success of first indication of L; and $1,000 for both L and D.
I am pumping and I am dreaming. God, may my dream come true! May patients have more choices!
Since Antimachine-kudo and later I posted daily information about shortable shares availability according to Interactive Broker, the truth is that almost every and each day, that number has been almost zero and in a few occasions, the number has been just a mere thousand, hundred, or even jokingly a dozen for quite some time now.
It suggests on the one hand, shorts cannot find any shares to continually short and thus continually manipulate the stock price down as was the case in the past, which is evidenced by the huge existing shorted share counts (about 10 millions plus maybe 4 millions naked shorts according to SmithonStock); on the other hand, Neil Woodford and some other funds, and more and more retail investors have bought and increased their shares to significantly reduce the float (which has scared the shorts, evidenced by their desperations and innovations in FUDs).
Conclusion: From a pure technical perspective, the only way shorts now can do to bring down the share price is to ask people to buy put contracts, in the disguise as hedging or not.
For the sake of patients, may God help us longs, thus help them in the form of a costly lesson!
Again, it has shown the true potential of DCVax-L which Germans seem grasp it very well. The whole world will soon get it right! Thanks.
There have been nothing but improved fundamentals. Knee-jerking retail investors should be weeded out like Turtle and the like, let alone the ones who have made the wrong bet such as Pyrr, RKmatter, etc.
After all those shares have been raked from those swing traders, and call sellers, the market has no way to go but up!
Vol. 4, No. 2, Pages 63-69 , DOI 10.2217/cns.14.54
Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme
Alia Hdeib1 & Andrew Edward Sloan*,1,2,3
*Author for correspondence: Andrew.Sloan@UHhospitals.org
DCVax® (Northwest Biotherapeutics, Inc., MD, USA) is a platform technology for delivering dendritic cell based therapeutic vaccines for a variety of cancers, including glioblastoma multiforme (GBM). DCVax®-L, one of the implementations of the DCVax platform, provides personalized active immunotherapy composed of autologous dendritic cells pulsed with autologous whole tumor lysate. Clinical trials with DCVax-L for GBM included previous Phase I/II clinical trials and an ongoing Phase III trial. Preliminary reports of patient outcomes after administration of the DCVax-L vaccine provide a promising therapeutic paradigm for patients with both initially diagnosed and recurrent GBM. Here we evaluate the current literature and clinical experience with the DCVax platform, with a particular focus on GBM treatment.
Simply put my friend, if nwbo stock price were not at $70, you might be right. We are sitting at $8, and how can anyone think there are too much enthusiasms. I think we are still lack of enthusiasms, let alone the media coverage which seems to just begin!
Great data for a patient population which has never responded to any treatment. 50% improvement of OS, which is unheard of !
Before any mention of nwbo preceded with the word of controversial, since last a couple weeks ago, it has abandoned that word. Today's article is yet another prove:
" Novartis' 'megablockbuster' heart drug LCZ696 wins another rave preview
April 23, 2015 By John Carroll
Readying itself for what looks like a blockbuster victory lap in the cardiovascular field, Novartis ($NVS) has notched boasting rights for its heart drug LCZ696, gaining recognition in the U.K. as a "promising innovative medicine" that could be made available to patients ahead of formal marketing approval.
Novartis Pharma Chief David Epstein
The Medicines and Healthcare products Regulatory Agency, or MHRA, granted the designation earlier today as an opening move toward early access. And they were moved by the PARADIGM-HF Phase III study, which demonstrated some clear benefits in reducing cardio deaths.
The MHRA isn't going to get any kickback from Novartis. Novartis pharma chief David Epstein has already dubbed this drug a "megablockbuster" in the making. And Thomson Reuters just days ago estimated 2019 sales for this drug at $3.73 billion.
The stellar data and a breakthrough reputation on both sides of the Atlantic helped chill expectations for Amgen's ($AMGN) newly approved heart treatment Corlanor (ivabradine). Even some concerns about a potential link to Alzheimer's--recently outlined by French researchers--has barely shaken the faith for LCZ696.
Last month the MHRA selected Merck's Keytruda, the closely-watched PD-1 checkpoint inhibitor, as the pioneer therapy to win early market access in the U.K. Northwest Biotherapeutics ($NWBO), meanwhile, won the first PIM last fall for its cancer vaccine DCVax.
"Despite widespread use of available treatments and implementation of NICE heart failure guidelines, outcomes remain poor for those diagnosed, with around 60% dying from heart failure within five years," says Hugh O'Dowd, the general manager at Novartis UK & Ireland. "" ...
I 100% agree with your stance, and I have never sold a single share since German HE news came out last year. Good luck to you and all who dare (will) hold their shares until our share price is at least on par with its peers'!
Not only we are better in various important aspects such as higher targeted patient populations, more intended treating varieties of cancer types, more advanced and simpler manufacturing process, and more favorable benefit/risk ratio, etc., we are well undervalued compared to our peers!
Now, it has been revealed that Cart-T is dead in any efforts to treat solid tumors!
Man, the sky is blue and indeed very blue for NWBO!
DCVax we believe! When its day comes with great treatments for patients with both operable and inoperable cancers of various types and forms, today's big pharms will be tomorrow's small pharms compared to Northwest Biotherapeutics!
Neil Woodford's now more than $100 million of investment in the company is absolutely gorgeous!
more than 50% improvement of OS on such patient population is unprecedented!
Yes this group is truly the sickest of the sick, but they can live more than 50% longer. Never ever have heard such great results!